Cyclacel Pharmaceuticals, Inc
Symbol: CYCC (NASDAQ)
6.71
▲ (0.68%) 0.045
Company Description:
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
Key Stats
- Today's Open: $6.65
- Today's High: $6.88
- Today's Low: $5.96
- Today's Volume: 139.56K
- Yesterday Close: $6.66
- Yesterday High: $7.11
- Yesterday Low: $6.65
- Yesterday Volume: 95.35K
- Last Min Volume: 1
- Last Min High: $6.705
- Last Min Low: $6.705
- Last Min VWAP: $6.705
Company Profile
- Name: Cyclacel Pharmaceuticals, Inc
- Website: https://cyclacel.com
- Listed Date: 2006-03-28
- Location: BERKELEY HEIGHTS, NJ
- Market Status: Active
- CIK Number: 0001130166
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $15.78M
- Round Lot: 100
- Outstanding Shares: 2.24M
- Asset Type: CS
RECENT FILINGS FOR CYCC
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-10 | 4 | View |
| 2025-09-05 | 425 | View |
| 2025-09-05 | 8-K | View |
| 2025-09-04 | 8-K | View |
| 2025-09-04 | 4 | View |
| 2025-09-04 | 4 | View |
| 2025-09-04 | 4 | View |
| 2025-09-02 | POS AM | View |
| 2025-09-02 | SCHEDULE 13G/A | View |
| 2025-09-02 | SCHEDULE 13G/A | View |
| 2025-09-02 | SCHEDULE 13G/A | View |
| 2025-09-02 | 3 | View |
| 2025-09-02 | 3 | View |
| 2025-09-02 | 3 | View |
| 2025-09-02 | 8-K | View |
| 2025-08-28 | 8-K | View |
| 2025-08-25 | DEFA14A | View |
| 2025-08-25 | 425 | View |
| 2025-08-25 | 424B3 | View |
| 2025-08-22 | POS AM | View |
Latest News on CYCC